| CPC C07D 271/06 (2013.01) [A61P 29/00 (2018.01); C07D 413/12 (2013.01)] | 19 Claims |
|
1. A compound of formula (I):
 wherein,
 represents a 5 membered heteroaryl ring, which in addition to the C═N shown contains one or more further heteroatoms independently selected from N, O and S; or
 represents a 6 membered heteroaryl ring, which in addition to the C═N shown optionally contains one or more further N atoms;
RA1 is C1-10 alkyl wherein the alkyl group is optionally substituted by one or more RA′ wherein RA′ is selected from the group consisting of halo, C1-6 haloalkyl, hydroxy, cyano, OG1, S(O)0-2G1, SF5, C3-7 cycloalkyl, 5-7-membered heterocyclyl, and phenyl, wherein the phenyl is optionally substituted by C1-2 haloalkyl, C1-2 haloalkoxy or one or more halo atoms; wherein said C3-7 cycloalkyl and said 5-7-membered heterocyclyl are optionally substituted by one or more groups selected from halo, C1-3 alkyl and C1-3 haloalkyl; and/or RA′ represents two alkyl groups which are attached to the same carbon atom and joined to form a C3-7 cycloalkyl ring; or
RA1 is selected from the group consisting of C2-10 alkenyl, C2-10 alkynyl, —(CH2)0-6—C3-10 cycloalkyl, —(CH2)0-6—C5-10 spirocycloalkyl, —(CH2)0-6-aryl and —O-aryl; wherein RA1 is optionally substituted by one or more RA″ wherein RA″ is selected from the group consisting of halo, C1-6 alkyl, C1-6 haloalkyl, hydroxy, cyano, OG1, S(O)0-2G1, SF5, (CH2)0-3C3-7 cycloalkyl, 5-7-membered heterocyclyl, and phenyl, wherein the phenyl is optionally substituted by C1-2 haloalkyl, C1-2 haloalkoxy or one or more halo atoms; wherein said C3-7 cycloalkyl and said 5-7-membered heterocyclyl are optionally substituted by one or more groups selected from halo, C1-3 alkyl and C1-3 haloalkyl; and/or RA1 is optionally substituted by two RA″ substituents wherein both RA″ are C1-6 alkyl which are attached to the same carbon atom and are joined to form a C3-7 cycloalkyl ring; and wherein the C3-10 cycloalkyl group is optionally fused to a phenyl ring which phenyl ring is optionally substituted by one or more halo atoms;
wherein G1 is C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, or (CH2)0-1phenyl, wherein G1 is optionally substituted by one or more G1′ wherein G1′ is selected from the group consisting of halo, C1-2 alkyl, C1-2 haloalkyl, hydroxy, cyano, nitro, C1-2 alkoxy and C1-2 haloalkoxy;
RA2 is selected from the group consisting of halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, hydroxy, cyano, nitro, NR1R2, OG2 and S(O)0-2G2;
wherein G2 is C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, or phenyl, wherein G2 is optionally substituted by one or more G2′ wherein G2′ is selected from the group consisting of halo, C1-2 alkyl, C1-2 haloalkyl, hydroxy, cyano, nitro, C1-2 alkoxy and C1-2 haloalkoxy; and
wherein R1 and R2 are independently H or C1-2 alkyl or, taken together, R1 and R2 may combine to form a 5-7 membered heterocyclic ring;
or RA2 is absent;
RB is selected from the group consisting of CH2COOH, CH2CH2COOH, CH2tetrazolyl and CH2CH2tetrazolyl, wherein RB is optionally substituted on an available carbon atom by one or more RB′ wherein RB′ is selected from the group consisting of difluoromethyl, trifluoromethyl and methyl; and/or wherein RB is optionally substituted by two RB′ groups, attached to the same carbon atom, that are joined to form a C3-6 cycloalkyl or a 4-6-membered heterocyclyl ring;
RC and RD are each independently H, C1-2 alkyl, hydroxy, C1-2 alkoxy or fluoro; or RC and RD may join to form a C3-5 cycloalkyl ring;
wherein
 in the compound of formula (I) represents:
 and
wherein,
the total number of carbon atoms in groups RA1 and RA2 taken together, including their optional substituents, is 5-14;
or a pharmaceutically acceptable salt and/or solvate thereof.
|